1 |
Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, and Davies DR (2005) The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 102: 10976-10980
DOI
ScienceOn
|
2 |
Choe J, Kelker MS, and Wilson IA (2005) Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309: 581-585
DOI
PUBMED
ScienceOn
|
3 |
Deininger S, Stadelmaier A, von Aulock S, Morath S, Schmidt RR, and Hartung T (2003) Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J Immunol 170: 4134-4138
DOI
|
4 |
Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, and Gay NJ (2003) Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J Biol Chem 278: 41443-41451
DOI
ScienceOn
|
5 |
Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, and Ikeda H (2003) Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 100: 171-194
DOI
ScienceOn
|
6 |
Gautam JK, Ashish, Comeau LD, Krueger JK, and Smith MF, Jr. (2006) Structural and functional evidence for the role of the TLR2 DD loop in TLR1/TLR2 heterodimerization and signaling. J Biol Chem 281: 30132-30142
DOI
ScienceOn
|
7 |
Hioe CE, Qiu H, Chend PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, and Nixon DF (1996) Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 14: 412-418
DOI
ScienceOn
|
8 |
Kim JI, Lee CJ, Jin MS, Lee CH, Paik SG, Lee H, and Lee JO (2005) Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 280: 11347-11351
DOI
ScienceOn
|
9 |
Kusumoto S, Fukase K, Fukase Y, Kataoka M, Yoshizaki H, Sato K, Oikawa M, and Suda Y (2003) Structural basis for endotoxic and antagonistic activities: investigation with novel synthetic lipid A analogs. J Endotoxin Res 9: 361-366
DOI
PUBMED
|
10 |
Miyake K (2003) Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 3: 119-128
DOI
PUBMED
ScienceOn
|
11 |
Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738
DOI
ScienceOn
|
12 |
Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, and Ulmer AJ (2005) Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 35: 282-289
DOI
ScienceOn
|
13 |
Erridge C, Bennett-Guerrero E, and Poxton IR (2002) Structure and function of lipopolysaccharides. Microbes Infect 4: 837-851
DOI
ScienceOn
|
14 |
Silverstein AM (2003) Darwinism and immunology: from Metchnikoff to Burnet. Nat Immunol 4: 3-6
DOI
PUBMED
ScienceOn
|
15 |
Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, and Aderem A (2000) The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 97: 13766-13771
DOI
ScienceOn
|
16 |
Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, and Akira S (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13: 933-940
DOI
ScienceOn
|
17 |
Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, and Mira JP (2005) The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 41 Suppl 7: S408-415
DOI
|
18 |
Kobe B and Kajava AV (2001) The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 11: 725-732
DOI
ScienceOn
|
19 |
Kajava AV (1998) Structural diversity of leucine-rich repeat proteins. J Mol Biol 277: 519-527
DOI
PUBMED
ScienceOn
|
20 |
Romagne F (2007) Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 12: 80-87
DOI
ScienceOn
|
21 |
Kanzler H, Barrat FJ, Hessel EM, and Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559
DOI
ScienceOn
|
22 |
Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, and Landmann R (2002) Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 186: 798-806
DOI
ScienceOn
|
23 |
Han SH, Kim JH, Martin M, Michalek SM, and Nahm MH (2003) Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun 71: 5541-5548
DOI
ScienceOn
|
24 |
Medzhitov R, Preston-Hurlburt P, and Janeway CA, Jr. (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397
DOI
PUBMED
ScienceOn
|
25 |
Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, and Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082
DOI
ScienceOn
|
26 |
Pancer Z and Cooper MD (2006) The evolution of adaptive immunity. Annu Rev Immunol 24: 497-518
DOI
ScienceOn
|
27 |
Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, and Akira S (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169: 10-14
DOI
PUBMED
|
28 |
Akira S and Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511
DOI
ScienceOn
|
29 |
Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, and Segal DM (2003) Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 24: 528-533
DOI
ScienceOn
|
30 |
Gay NJ and Keith FJ (1991) Drosophila Toll and IL-1 receptor. Nature 351: 355-356
PUBMED
|
31 |
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, and Kimoto M (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777-1782
DOI
ScienceOn
|
32 |
Kobe B and Deisenhofer J (1994) The leucine-rich repeat: a versatile binding motif. Trends Biochem Sci 19: 415-421
DOI
PUBMED
ScienceOn
|
33 |
Iwaki D, Nishitani C, Mitsuzawa H, Hyakushima N, Sano H, and Kuroki Y (2005) The CD14 region spanning amino acids 57-64 is critical for interaction with the extracellular Toll-like receptor 2 domain. Biochem Biophys Res Commun 328: 173-176
DOI
ScienceOn
|
34 |
Park BS, Song DH, Kim HM, Choi BS, Lee H, and Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature
DOI
ScienceOn
|
35 |
Ohto U, Fukase K, Miyake K, and Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316: 1632-1634
DOI
PUBMED
ScienceOn
|
36 |
Nunez Miguel R, Wong J, Westoll JF, Brooks HJ, O'Neill LA, Gay NJ, Bryant CE, and Monie TP (2007) A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS ONE 2: e788
DOI
PUBMED
|
37 |
Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, and Schumann RR (2003) Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 278: 15587-15594
DOI
ScienceOn
|
38 |
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, and Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200
DOI
ScienceOn
|
39 |
O'Neill LA (2004) TLRs: Professor Mechnikov, sit on your hat. Trends Immunol 25: 687-693
DOI
PUBMED
ScienceOn
|
40 |
Viriyakosol S, Tobias PS, Kitchens RL, and Kirkland TN (2001) MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 276: 38044-38051
PUBMED
|
41 |
Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, and Davies DR (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320: 379-381
DOI
PUBMED
ScienceOn
|
42 |
Miyake K (2006) Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 12: 195-204
DOI
PUBMED
ScienceOn
|
43 |
Gibbard RJ, Morley PJ, and Gay NJ (2006) Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling. J Biol Chem 281: 27503-27511
DOI
ScienceOn
|
44 |
Nakata T, Yasuda M, Fujita M, Kataoka H, Kiura K, Sano H, and Shibata K (2006) CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cell Microbiol 8: 1899-1909
DOI
ScienceOn
|
45 |
West AP, Koblansky AA, and Ghosh S (2006) Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 22: 409-437
DOI
ScienceOn
|
46 |
Manukyan M, Triantafilou K, Triantafilou M, Mackie A, Nilsen N, Espevik T, Wiesmuller KH, Ulmer AJ, and Heine H (2005) Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur J Immunol 35: 911-921
DOI
ScienceOn
|
47 |
Morath S, Geyer A, and Hartung T (2001) Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 193: 393-397
DOI
ScienceOn
|
48 |
Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, and Rossignol DP (2003) Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304: 1093-1102
DOI
ScienceOn
|
49 |
Beutner KR, Tyring SK, Trofatter KF, Jr., Douglas JM, Jr., Spruance S, Owens ML, Fox TL, Hougham AJ, and Schmitt KA (1998) Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 42: 789-794
PUBMED
|
50 |
Gay NJ and Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141-165
DOI
ScienceOn
|
51 |
Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, and Triantafilou K (2006) Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 281: 31002-31011
DOI
ScienceOn
|
52 |
Kim HM, Oh SC, Lim KJ, Kasamatsu J, Heo JY, Park BS, Lee H, Yoo OJ, Kasahara M, and Lee JO (2007a) Structural diversity of the hagfish variable lymphocyte receptors. J Biol Chem 282: 6726-6732
DOI
ScienceOn
|
53 |
Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, Espevik T, and Golenbock DT (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8: 772-779
DOI
ScienceOn
|
54 |
O'Neill LA and Bowie AG (2007) The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364
DOI
ScienceOn
|
55 |
Jin MS and Lee JO (2008) Application of hybrid LRR technique to protein crystallization. BMB Rep 41: 353-357
DOI
PUBMED
|
56 |
Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, and Lee JO (2007b) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917
DOI
ScienceOn
|
57 |
Tanamoto K and Azumi S (2000) Salmonella-type heptaacylated lipid A is inactive and acts as an antagonist of lipopolysaccharide action on human line cells. J Immunol 164: 3149-3156
DOI
|
58 |
Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, Coskun M, Cilli A, and Yegin O (2004) The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 23: 219-223
DOI
ScienceOn
|
59 |
Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K, and Kuroki Y (2007) Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate tolllike receptors. BMC Genomics 8: 124
DOI
PUBMED
ScienceOn
|
60 |
Kobe B and Deisenhofer J (1995) Proteins with leucine-rich repeats. Curr Opin Struct Biol 5: 409-416
DOI
ScienceOn
|